Collectively, these results suggest that while deletion of TRAF6 has a lessened impact in reducing obesity, TAK1 drastically reduces HFD-induced increase in adipose tissue mass, potentially through reducing adipocyte hypertrophy and survival. Here, MAP3K7 is linked to obesity due to melanocortin 4 receptor deficiency.